- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04744740
In-Home Sleep Monitoring to Detect Suicide Risk in Veterans
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Suicide is a devastating event that occurs at a very low base rate, rendering detection of acute suicide risk one of the signal challenges in behavioral science. Advancement in the detection of imminent risk requires new modalities of intensive, longitudinal data collection that are both acceptable and scalable. Recent developments in commercial, actigraphic sleep recording systems have opened a new avenue of approach to this challenge, enabling the automated collection and daily review of sleep scheduling and sleep heart rate (HR), both of which have demonstrated associations with suicidality in prior studies. Our team, comprising Drs. Steven Woodward (Director of the Sleep and Psychophysiology Laboratory of the National Center for PTSD), Rebecca Bernert (Director of the Suicide Prevention Center, Stanford University School of Medicine), Christina Khan (Director of the Thrive Clinic, Stanford University School of Medicine), and Wilfred Pigeon (Director of the Center of Excellence in Suicide Prevention, Department of Veterans Affairs) will pursue the following Aims.
AIM 1: To assess, in U.S. military veterans diagnosed with posttraumatic stress disorder (PTSD), whether sleep schedule variability and sleep heart rate, recorded in the home for one month using a low-cost, zero-burden, actigraphic sleep measurement system, can distinguish those who are at elevated actuarial risk for suicide from those who are not.
AIM 2: To assess, in U.S. military veterans diagnosed with PTSD, whether elevated sleep schedule variability and elevated sleep heart rates can predict increased suicidal ideation over a clinically-relevant surveillance period of two months.
The proposal is founded on observational and epidemiological studies supporting associations between sleep disturbance, basal heart rate and suicidality, including important contributions from Co-Is Bernert and Pigeon (1-12). Also supportive of the proposal are new observations from a sample of 71 U.S. Military veterans with deployment-related PTSD studied by the PI during inpatient PTSD treatment. In this sample, after adjusting for depressed mood and body mass index (BMI), sleep heart rate was 3.8 BPM higher in those endorsing current ideation and a history of attempts than in those denying both. The investigators also describe in detail below a supportive case observed in Dr. Woodward's laboratory which, to our knowledge, represents the first extended acquisition of sleep behavior prior to a serious suicide attempt.
The proposal leverages the PI's expertise in zero-burden, mattress-actigraphic sleep recording originally motivated by the observation that PTSD patients rarely manifest sleep disturbances in the laboratory. The aforementioned data were obtained employing a high-accuracy, non-commercial, mattress actigraphic system developed by the PI (13-15), which was found acceptable to > 95% of the 900+ veteran PTSD inpatients with whom it has been used at the Trauma Recovery Program (TRP) at the VA Palo Alto Health Care System (~40,000 nights of recording). The proposed study will employ a low-cost, commercially-available alternative, the Sleepace RestOn, that can be mailed and user-installed. This system is also zero-burden as there is nothing to put on, take off, charge, or upload. In our pilot work, it has proven acceptable to veteran outpatients at high risk for suicide. Moreover, though its connection to a tablet computer, this system provides daily, web-based access to the raw actigraphic data enabling the direct verification of data quality and the application of custom algorithms to extract movement, heart rate, and respiratory amplitude.
Aim 1 will attempt to replicate and extend the aforementioned observations made in PTSD inpatients with and without suicidal ideation and histories of attempts in PTSD outpatients studied in the home. Aim 2 will attempt to replicate and extend Co-I Bernert's study demonstrating, in high-risk young adults, that weekly changes in sleep schedule variability predict weekly changes in suicidal ideation (1). Bernert's study period will be extended from three weeks to two months, and sleep heart rate will be included as a predictor. Suicide symptoms will be assessed weekly by telephone using the Depression Symptom Index - Suicide Severity (DSI-SS; 16), a brief, psychometrically-sound measure of suicide ideation intensity yielding a score from 0 to 12 (17). Mixed effects modeling (18) will be employed, and with respect to Aim 2, the temporal precedence of changes in sleep to changes in suicidal ideation intensity will be tested in order confirm that sleep changes meet criteria for true risk-factors (19). An established partnership with VA Suicide Prevention Coordinators (SPCs) will facilitate recruitment from the actuarial REACH VET list (20) and local hospital high-risk list while maximizing participant safety. An exploratory aim will estimate the contribution of certain participant factors likely to impact sleep scheduling or its measurement, in-bed media consumption, hypnotic medication, CPAP use, and alcohol/substance use. In the case of a positive study outcome, a multi-site R01 will be proposed including centralized data collection and review at the VA Center of Excellence for Suicide Prevention in Canandaigua, NY, under the direction of Co-I Pigeon, implementation science and health economic aims developed in collaboration with Co-I Marshall, and exploratory integration into the REACH VET algorithm.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304
- Recruiting
- VA Palo Alto Health Care System
-
Contact:
- Esther Eng, BA
- Phone Number: 650-239-2818
- Email: eng@pavir.org
-
Contact:
- Elaine Staats, BA
- Phone Number: 650-239-2803
- Email: estaats@pavir.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- PTSD or partial PTSD
- Status on clinical high-risk list and subject to enhanced surveillance by the suicide prevention activity and staff at VAPAHCS (or not)
- Adequate cell phone service and/or wireless wife connectivity in sleeping quarters.
Exclusion Criteria:
- Schizophrenia or psychotic disorder, autism-spectrum diagnoses medically unstable
- unable to speak and read English or otherwise incapable of providing informed consent
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
PTSD+Suicidal Ideation
US Military Veterans diagnosed with PTSD and identified via the REACH VET or local high-risk list as requiring intensified surveillance by their VA's Suicide Prevention Coordinators in collaboration with their Primary Care Providers
|
in-home, nightly, zero-burden objective quantification of sleep scheduling and sleep heart rate via a mattress-top sensor (Sleepace RestOn) + ad lib quantification of blood SaO2 via a ring-based sensor (Bodimetrics Circul) + ad lib quantification of sleep and waking activity and heart rate via a wrist-worn sensor (Garmin Vivosmart 4)
|
|
PTSD-Suicidal Ideation
US Military Veterans diagnosed with PTSD not identified as requiring intensified surveillance by their VA's Suicide Prevention Coordinators in collaboration with their Primary Care Providers
|
in-home, nightly, zero-burden objective quantification of sleep scheduling and sleep heart rate via a mattress-top sensor (Sleepace RestOn) + ad lib quantification of blood SaO2 via a ring-based sensor (Bodimetrics Circul) + ad lib quantification of sleep and waking activity and heart rate via a wrist-worn sensor (Garmin Vivosmart 4)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Between-group differences in sleep scheduling variability
Time Frame: 30 days
|
Between-group differences in sleep scheduling variability
|
30 days
|
|
Between-group differences in sleep heart rate
Time Frame: 30 days
|
Between-group differences in sleep heart rate
|
30 days
|
|
Within-group (PTSD+Suicidal Ideation) covariance between objective sleep measures and suicidal ideation
Time Frame: 60 days
|
Within-group (PTSD+Suicidal Ideation) covariance between objective sleep measures and suicidal ideation
|
60 days
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WOS0023AGG
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
- Analytic Code
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep Disturbance
-
Università degli Studi di BresciaCompletedSleep Phase Rhythm DisturbanceItaly
-
Zhuan ZhangNot yet recruitingCircadian Rhythm | Postoperative Sleep DisturbanceChina
-
The First Affiliated Hospital of Xiamen UniversityNot yet recruitingPostoperative Sleep Disturbance
-
Our Lady's Hospice and Care ServicesSt Vincent's University Hospital, IrelandEnrolling by invitation
-
University of BergenGlamoxCompletedSleep | Sleep Deprivation | Shift-Work Related Sleep DisturbanceNorway
-
Riphah International UniversityCompletedSleep Disturbance in AthletesPakistan
-
Sam Houston State UniversityThe University of Texas Health Science Center, Houston; Memorial Hermann Texas...CompletedSleep Disturbance in Hospitalized Antepartum PatientsUnited States
-
Pacific UniversityCompletedInsomnia | Shift-Work Related Sleep DisturbanceUnited States
-
Erasmus Medical CenterNational Institute for Public Health and the Environment (RIVM); Netherlands...CompletedShift-Work Related Sleep DisturbanceNetherlands
-
Seoul National University HospitalNot yet recruiting
Clinical Trials on in-home sleep recording
-
Direction Centrale du Service de Santé des ArméesRecruitingSleep Disorder | Heat; ExcessFrance
-
University Hospital, ToulouseRecruiting
-
Fondation Ophtalmologique Adolphe de RothschildTeva Pharmaceutical Industries, Ltd.Completed
-
Koç UniversityKoc Healthcare Istanbul American Hospital, Marmara University HospitalUnknownPneumonia | Obstructive Sleep Apnea | COVIDTurkey
-
Sunnybrook Health Sciences CentreUnity Health TorontoRecruitingObstructive Sleep Apnea | Alzheimer Disease | Mild Cognitive Impairment | Vascular Dementia | Dementia With Lewy Bodies | Mixed Dementia | Parkinsons Disease With DementiaCanada
-
Sunnybrook Health Sciences CentreWomen's College HospitalRecruitingHypertension | Obstructive Sleep ApneaCanada
-
Karl Landsteiner Institute for Clinical Epilepsy...AIT Austrian Institute of Technology GmbH; Brainhero GmbHTerminated
-
Stanford UniversityCompletedObstructive Sleep ApneaUnited States
-
University Hospital, MontpellierCompletedIschemic Stroke | Sleep Apnea | Cerebral Infarct | Periodic Limb Movement DisorderFrance
-
Direction Centrale du Service de Santé des ArméesRecruitingPost-traumatic Stress DisorderFrance